When Gilead Sciences puts a price on its antiviral drug remdesivir as a treatment for Covid-19 in the coming weeks, the broker SVB Leerink thinks sales will rise into the billions of dollars. So analyst Geoffrey Porges raised the stock (ticker: GILD) to Outperform in a Wednesday morning note, saying its $73 shares could rise to $94.
SVB Leerink Upgrades Gilead From Market Perform To Outperform, Raises PT From $85 To $94
Anm.: 2 Prognosen VOR (!) der Astra Z.- Thematik....Konsens bei 30 Analysten bisher : HOLD
CNN von gestern :
Now that the free supply is almost gone, there are concerns Gilead will charge a high price.
"The price that Gilead can charge, as with any pharmaceutical in America, appears to be the sky's the limit -- whatever sick and dying people will pay," said Rep. Lloyd Doggett, a Texas Democrat who chairs the House Ways and Means health subcommittee.
edition.cnn.com/2020/06/07/health/...t-coronavirus/index.html
Anm.: (mein) Fazit : geringe Verfügbarkeit, immense Nachfrage, Preis nach oben hin offen.
Und wir reden hier nur von Remdesivir.....
Meine Meinung: es wird KEIN Mergen geben, aber alleine dem Gerücht geschuldet.... könnte der heutige Kurs auch +10 % oder mehr steigen...
Zurück
Weiter
